SecBot SecBot
Biotech Drug Report Generated Aug 1, 2026

DAWNZERA

IONS·IONIS PHARMACEUTICALS INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (FDA, NDA 219407)
Time to market
Already approved and on the U.S. market, FDA approval Aug 21, 2025 (NDA 219407, New Molecular Entity).
Why 3/10
No scheduled regulatory decision for DAWNZERA in the next ~12 months: its FDA approval (Aug 21, 2025) already passed with a flat stock reaction (-0.28% 1-day, -1.49% 5-day), so this is an approved, commercial-stage asset inside a multi-program company whose dated 2026 binaries (zilganersen PDUFA Sep 22, 2026; bepirovirsen PDUFA Oct 26, 2026) belong to other drugs, capping impactScore at 3-5 territory for a marketed product.
Actionable Insight NEUTRAL

DAWNZERA itself is not a near-term trading catalyst, the binary event (FDA approval) already happened in Aug 2025 and did not move IONS. For a non-medical investor, Dawnzera matters as part of Ionis' commercial portfolio story; the next hard price drivers for IONS stock are the zilganersen PDUFA (Sep 22, 2026) and bepirovirsen PDUFA (Oct 26, 2026). Watch quarterly earnings disclosures (10-Q filed Jul 29, 2026) for Dawnzera launch metrics, and note the rising FINRA short position (~12.13% of est. shares outstanding at the 7/15/2026 settlement) and July insider sales as sentiment headwinds.

Price Chart

Loading chart...

Executive Summary

DAWNZERA (generic: donidalorsen, code IONIS-PKK-LRx) is Ionis Pharmaceuticals' wholly-owned antisense-oligonucleotide preventive for hereditary angioedema (HAE), approved by the FDA on Aug 21, 2025 as a New Molecular Entity (NDA 219407) in an autoinjector presentation; its supporting Phase 2 extension study in HAE is complete. The approval was a non-event for the stock (IONS -0.28% 1-day, -1.49% 5-day around the date). Dawnzera is one of several marketed Ionis drugs, the company's dated 2026 catalysts are other programs (zilganersen PDUFA Sep 22, 2026; bepirovirsen PDUFA Oct 26, 2026).

How It Works

Dawnzera is an antisense drug: a short piece of synthetic genetic material that reduces the body's production of prekallikrein (PKK), a liver-made protein involved in the pathway that drives the sudden swelling attacks of hereditary angioedema (HAE). By keeping PKK levels low, it is meant to prevent attacks rather than treat them after they start. It is given by subcutaneous injection via an autoinjector (per the approved product name), making it a home-use prophylactic.

Trial Status

FDA-approved Aug 21, 2025 as a Type 1 New Molecular Entity (donidalorsen) per the OPENFDA catalyst record. Supporting data include a completed Phase 2 extension study of donidalorsen (IONIS-PKK-LRx) in hereditary angioedema (NCT04307381, completed Jan 2025, has results); the product is now in commercial launch in the autoinjector presentation.

The Two-Sided Case

▲ Bull Case4
Already approved and revenue-generating: FDA approval Aug 21, 2025 as a Type 1 New Molecular Entity, donidalorsen (OPENFDA catalyst record, NDA 219407), removing the approval binary risk.
Self-administered autoinjector presentation ('DAWNZERA (AUTOINJECTOR)') positions it as a convenient home-use prophylactic in a defined rare-disease population (Hereditary Angioedema, per the completed NCT04307381 extension study).
Company-level support: IONS analyst consensus is 16 Buy + 11 Strong Buy vs 6 Hold and 0 Sell, with a mean price target of $90.8 vs ~$51.6 price (≈73.8% implied upside) as of Jul 31, 2026.
Dawnzera is one asset in a broad Ionis portfolio with multiple later-2026 PDUFA catalysts (zilganersen, bepirovirsen), so the company's thesis does not hinge on this one drug.
▼ Bear Case5
The approval itself did not move the stock: local catalyst-outcome data shows IONS fell -0.28% (1-day) and -1.49% (5-day) around the Aug 21, 2025 approval, the event was largely priced in.
No DAWNZERA-specific dated binary in the next ~12 months (no pending PDUFA/sNDA for this drug in local FDA catalyst data), so near-term IONS upside depends on other programs, not this product.
Rising bearish positioning at the company level: FINRA short interest grew +15.02% at the 7/15/2026 settlement to ~20.0M shares, ~12.13% of estimated shares outstanding (FINRA estimate, not float; days to cover 3.68), and weighted short-volume ratio was ~0.57 over the last 40 sessions.
Mixed sentiment signals: Wolfe Research downgraded IONS (Outperform to Peer Perform, Jul 16, 2026) and multiple insiders sold in early July (e.g., 15,000 sh at $85.46 and 10,111 sh at $85.42; planned-sale status unknown).
Dawnzera competes in a niche rare-disease market with several established HAE prophylactics; without live web access this session, launch-ramp and market-share data could not be independently verified.

Upcoming Catalysts

  • None scheduled for DAWNZERA itself (already approved, commercial stage)
  • Company-level, other drugs: zilganersen PDUFA action date Sep 22, 2026 (Alexander disease)
  • Company-level, other drugs: bepirovirsen NDA Priority Review PDUFA date Oct 26, 2026 (chronic hepatitis B)
  • Quarterly earnings (next 10-Q / earnings release) for Dawnzera launch revenue commentary

Source Filing

The SecBot filing or press-release report that triggered this drug report:

IONIS PHARMACEUTICALS INC 8-K IONS ·Originating report

Sources · 2

Hover a chip for the title
1 sec.gov2 sec.gov